FDA Approves Avlayah as Treatment of Hunter Syndrome

Why It Matters

The therapy addresses a critical unmet need by targeting both central and peripheral disease, potentially altering the disease trajectory for patients with Hunter syndrome. Its approval also validates a new class of biologics capable of crossing the blood‑brain barrier, opening pathways for other neurodegenerative disorders.

Key Takeaways

• First FDA‑approved therapy crossing blood‑brain barrier for Hunter
• Reduces CSF heparan sulfate 91% by week 24
• Normalizes urine glycosaminoglycans in 90% of patients
• Infusion reactions drop from 83% to 41% over time
• Ongoing phase 2/3 COMPASS trial compares to standard enzyme therapy

Pulse Analysis

Hunter syndrome, or mucopolysaccharidosis type II, is a rare X‑linked lysosomal storage disorder affecting roughly 1 in 150,000 newborns. The deficiency of iduronate‑2‑sulfatase leads to accumulation of glycosaminoglycans, causing progressive organ damage and, in most patients, severe neurocognitive decline. Until now, enzyme replacement therapies have been limited to peripheral tissues because large proteins cannot cross the blood‑brain barrier, leaving neurologic manifestations largely untreated. Denali’s TransportVehicle platform leverages a proprietary enzyme‑carrier system to ferry the therapeutic across the barrier, representing a paradigm shift in treating lysosomal diseases with central nervous system involvement.

The FDA’s accelerated approval rests on a multicenter phase 1/2 study of 47 boys, where weekly intravenous Avlayon produced a 91 % drop in cerebrospinal fluid heparan sulfate after 24 weeks and restored biomarker levels to those of healthy controls in 93 % of participants. Parallel reductions in neurofilament light and urinary glycosaminoglycans suggest both neuronal and systemic disease modification. Safety signals were manageable, with infusion‑related reactions declining from 83 % early in treatment to 41 % after three years. These data provide the first concrete evidence that a biologic can normalize central disease markers in Hunter syndrome.

The approval creates a new revenue stream for Denali, whose market‑cap is poised to rise as insurers negotiate coverage for a therapy that addresses an unmet neurologic need. More importantly, the success of the TransportVehicle platform validates a drug‑delivery approach that could be repurposed for other neurodegenerative and lysosomal disorders, such as Tay‑Sachs or Fabry disease. Investors and competitors will watch the ongoing COMPASS phase 2/3 trial, which pits Avlayon against existing enzyme therapies across a broader age range, to gauge long‑term efficacy and payer acceptance. If the confirmatory study confirms these early gains, Avlayon could become the benchmark for blood‑brain‑barrier‑penetrant biologics.